Recon: Pfizer touts long-term efficacy data for COVID vaccine in adolescents; House panel seeks interview with Hahn

• CDC expands eligibility for Covid-19 booster shots to all adults (STAT)
• Johnson & Johnson touts ‘golden moment’ to pursue pharma-led future (FT)
• Concerns Grow Over Safety of Aduhelm After Death of Patient Who Got the Drug (NYTimes)
• Bluebird, after delays, gets speedy FDA review for beta thalassemia gene therapy (BioPharmaDive)
• CBO: Democrats' package saves about $160B on drug prices (The Hill)
• A worrisome safety signal slows Merck's HIV ambitions (BioPharmaDive)
• Pfizer's COVID-19 vaccine trial data shows long-term efficacy in adolescents (Reuters) (STAT)
• FDA delays its decision on Bristol Myers' $13B heart drug another three months (Endpoints)
• The Elizabeth Holmes Trial: Theranos Founder Takes the Stand (WSJ)
• House COVID-19 panel seeks interview with former Trump FDA leader Hahn (The Hill)
• FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism (FDA)

• EQT, BioNTech investor consider bid for Novartis arm Sandoz -report (Reuters)
• EU says decision on J&J COVID-19 vaccine booster dose 'within weeks' (Reuters) (EMA)
• EMA starts review of Paxlovid for treating patients with COVID-19 (EMA)
• How Covid has raised the profiles and fortunes of India’s pharma entrepreneurs (FT)
• Japan sees 'drug lag' as foreign pharmas pass up the market amid pricing pressure, industry group warns (Fierce)
• First COVID vaccine doses donated by EU begin arriving in Africa- GAVI (Reuters)
• Israel eyes setting up its own vaccine production facility (Reuters)
• Resumption of India's COVAX vaccine supply delayed by Nepal – sources (Reuters)
• Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development (Reuters)

• Name that vaccine: From Comirnaty to Spikevax to Nuvaxovid, Covid-19 shots' brand names remain little-known (Endpoints)
• Activists urge Biden to push for intellectual property waiver for COVID-19 vaccines (Reuters)
• 90% of U.S. federal employees have received at least one COVID-19 dose - White House (Reuters)
• First Known Covid Case Was Vendor at Wuhan Market, Scientist Says (NYTimes)
• Biden administration suspends enforcement of business vaccine mandate to comply with court order (CNBC)

• Biomanufacturing companies getting hit by hackers potentially linked to Russia (The Hill)
• FDA is temporarily suspending certain Clozapine REMS program requirements to ensure continuity of care for patients taking clozapine (FDA)
• Labcorp adds to drug development, device testing services with Toxikon buy (Fierce)
• Limited access to antibiotics is driving resistance, warns watchdog (FT)
• Pressure grows for funding to tackle ‘silent pandemic’ of antimicrobial resistance (FT)
• Verily’s Amy Abernethy hints at clinical trial blueprint for 2022 (STAT)
• BD upsizes San Diego presence with new 220K-square-foot biosciences R&D facility (Fierce)
• Amgen's Otezla, Repatha and biosimilars put on notice, with challenging years ahead (Fierce)
• Safety threat forces Enanta to scrap HBV trials — sending discovery team back to drawing board (Endpoints)
• Daiichi Sankyo looks to bring FLT3 drug back from the dead with late-stage win in early AML patients (Endpoints)
• Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal (Endpoints)
• BioCryst gets massive cash infusion to the tune of $350M, thanks to old and new investors (Endpoints)
• Connect Biopharma celebrates a mid-stage win for its Dupixent rival, but shares tank after investors clamor for data (Endpoints)
• Xencor says goodbye to its former lead drug, selling all rights to Lonnie Moulder's new startup (Endpoints)

• Pear's digital therapeutic for alcohol use disorder bears fruit with FDA breakthrough tag (Fierce)
• FDA reemphasizes heart perforation risks of leadless pacemakers, with market set to grow (Fierce)
• Stryker dismisses robotics threat from J&J, Zimmer with bullish forecast (MedtechDive)
• Latest breakthrough device designations go to brain-computer interface, exo-suit (MedtechDive)
• EU’s First IVDR Expert Panel View Published (MedtechInsight)

• Sanofi clinches 2nd bellwether win in chemotherapy hair loss litigation (Fierce)
• Bayer, Amgen Unit Drop IP Suit Over Cancer Drug Generic (Law360)
• Businesses Appeal £100M CMA Fine For Overpriced Drug (Law360)
• Illumina Defends Validity Of DNA Sequencing Patents At Trial (Law360)